论文部分内容阅读
目的探讨蚓激酶胶囊治疗脑梗死的临床疗效。方法将317例脑梗死患者随机分为添加蚓激酶胶囊治疗组和对照组。比较两组治疗前后的血液流变学实验室指标、美国国立卒中量表(The National Institutes of Health Stroke Scale,NIHSS)评分及疗效。结果治疗组患者治疗前、后血液流变学各指标间差异均有显著性意义,且两组患者经治疗后纤维蛋白原含量、红细胞聚集指数、红细胞变形指数、血浆黏滞度间差异均有显著性(P<0.05)。治疗后,7天起治疗组NIHSS评分对照组明显减少,28天后差异更显著(P<0.01)。治疗后28天疗效评定,治疗组总有效率为86.2%,对照组总有效率为76.6%,两组患者疗效差异有显著性意义(P<0.05)。结论蚓激酶胶囊治疗脑梗死疗效显著,且安全可靠,为脑梗死的治疗提供了选择的机会。
Objective To investigate the clinical efficacy of lumbrokinase capsules in the treatment of cerebral infarction. Methods 317 patients with cerebral infarction were randomly divided into treatment group and control group. The hemorheology laboratory indexes, the National Institutes of Health Stroke Scale (NIHSS) score and the curative effect were compared between the two groups before and after treatment. Results Before and after treatment, the differences of hemorheology between the two groups were significant, and there was significant difference in fibrinogen content, erythrocyte aggregation index, erythrocyte deformability index and plasma viscosity between the two groups after treatment Significance (P <0.05). After treatment, the NIHSS score of the treatment group decreased significantly from the 7th day after treatment, and the difference was more significant after 28 days (P <0.01). After 28 days of treatment, the total effective rate was 86.2% in the treatment group and 76.6% in the control group, with significant difference between the two groups (P <0.05). Conclusion Lumbukinase capsules have a significant therapeutic effect on cerebral infarction and are safe and reliable, which provides a chance for the treatment of cerebral infarction.